Cynapsus Therapeutics Begins Trading on OTCQX®
Troutman Sanders was mentioned in many June articles and press releases, such as Law360 and The Street, for advising Canada-based Cynapsus Therapeutics Inc. with its previously announced United States initial public offering of 5,175,000 common shares sold to the public at US$14.00 per share for gross proceeds of approximately US$72.5 million and its listing on the NASDAQ Global Market. The offering was underwritten by Bank of America Merrill Lynch, Normura and Noble Life Science Partners.
Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a Phase 3, fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson’s disease.
Corporate partner Tom Rose was the lead on a team of Troutman Sanders attorneys – Heather Ettinger (IP), Mark Goldsmith (Tax), Amie Broder (Tax), Dave Meyers (Corporate), Shona Smith (Corporate), Lisa Raines (Corporate), Kristen O’Connor (Corporate) and Dan Howell (Corporate) and many others – who assisted Cynapsus on the deal.